Drug intelligence / Profile preview

BHT002

Development stage: Preclinical
Lead developer: Bio-Hybrid Therapeutics
Modality: Antibody-Based Therapeutics
Administration: Injection

Overview

BHT002 (also known as BHT 002D) is a patent-pending human immune globulin biologic being developed by Bio-Hybrid Therapeutics. It is designed as a passive immune globulin therapy to treat and prevent allergic reactions and symptoms associated with specific protein allergens. By providing neutralizing antibodies, BHT002 aims to block allergen-triggered responses. The drug is currently being explored for the treatment of multiple allergic and inflammatory conditions, including atopic dermatitis (AD), anaphylaxis, rhinitis, and irritable bowel syndrome (IBS). Bio-Hybrid Therapeutics positions this candidate as a pioneering approach to stopping atopic dermatitis.

Other names: Immune globulin (human)

Beyond the preview

Go deeper on BHT002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BHT002.

Explore the full profile